Docetaxel plus epirubicin (DE) vs docetaxel plus capecitabine (DC) as 1st line treatment in patients with locally advanced and metastatic breast cancer: a subgroup analysis for elderly patients of a multicenter randomized phase III trial from the Hellenic Oncology Research Group (HORG)

被引：0
|
作者：
Vamvakas, L. [1 ]
Karampeazis, A. [1 ]
Ardavanis, A. [1 ]
Souglakos, I. [1 ]
Kalbakis, K. [1 ]
Vardakis, N. [1 ]
Kouroussis, Ch. [1 ]
Malamos, N. [1 ]
Varthalitis, I. [1 ]
Mavroudis, D. [1 ]
机构：
[1] Univ Gen Hosp Heraklion, Crete, NE USA
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2007年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S49 / S49
页数：1
相关论文
共 50 条
  • [31] Prospective multicenter randomized phase III studies of weekly vs standard docetaxel (D2) plus doxorubicin (D4) for 1st line treatment of metastatic breast cancer (MBC)
    Stemmler, H. J.
    Herrmann, N.
    Heinemann, V.
    Vehling-Kaiser, U.
    Schaefer, M.
    Abenhardt, W.
    Kiechle, M.
    Harbeck, N.
    EJC SUPPLEMENTS, 2004, 2 (03): : 129 - 129
  • [32] Elderly subset analysis of randomized phase III study comparing pemetrexed plus carboplatin with docetaxel plus carboplatin as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer
    Pereira J.R.
    Cheng R.
    Orlando M.
    Kim J.-H.
    Barraclough H.
    Drugs in R&D, 2013, 13 (4) : 289 - 296
  • [33] Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
    Hans-Joachim Lück
    Andreas Du Bois
    Sibylle Loibl
    Iris Schrader
    Jens Huober
    Volker Heilmann
    Matthias Beckmann
    Ann Stähler
    Christian Jackisch
    Michael Hubalek
    Barbara Richter
    Elmar Stickeler
    Holger Eidtmann
    Christoph Thomssen
    Michael Untch
    Kerstin Wollschläger
    Tibor Schuster
    Gunter von Minckwitz
    Breast Cancer Research and Treatment, 2013, 139 : 779 - 787
  • [34] Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
    Lueck, Hans-Joachim
    Du Bois, Andreas
    Loibl, Sibylle
    Schrader, Iris
    Huober, Jens
    Heilmann, Volker
    Beckmann, Matthias
    Staehler, Ann
    Jackisch, Christian
    Hubalek, Michael
    Richter, Barbara
    Stickeler, Elmar
    Eidtmann, Holger
    Thomssen, Christoph
    Untch, Michael
    Wollschlaeger, Kerstin
    Schuster, Tibor
    von Minckwitz, Gunter
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (03) : 779 - 787
  • [35] Clinical phase Ib trial of L-NMMA plus docetaxel in the treatment of refractory locally advanced or metastatic triple negative breast cancer patients
    Chang, Jenny
    Rodriguez, Angel
    Ensor, Joe
    CANCER RESEARCH, 2017, 77
  • [36] Gemcitabine Plus Docetaxel Versus Docetaxel in Patients With Predominantly Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer: A Randomized, Phase III Study by the Danish Breast Cancer Cooperative Group
    Nielsen, Dorte L.
    Bjerre, Karsten D.
    Jakobsen, Erik H.
    Cold, Soren
    Stenbygaard, Lars
    Sorensen, Peter G.
    Kamby, Claus
    Moller, Susanne
    Jorgensen, Charlotte L. T.
    Andersson, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (36) : 4748 - 4754
  • [37] Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group
    N. Kentepozidis
    A. Kotsakis
    A. Soultati
    S. Agelaki
    Ch. Christophylakis
    M. Agelidou
    L. Chelis
    P. Papakotoulas
    L. Vamvakas
    Z. Zafiriou
    G. Samonis
    V. Georgoulias
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 605 - 612
  • [38] Docetaxel compared with vinorelbine in elderly patients with advanced non-small cell lung cancer (NSCLC): A randomized phase II Hellenic Oncology Research Group trial
    Karampeazis, A.
    Vamvakas, L.
    Agelidou, A.
    Chandrinos, V.
    Tsiafaki, X.
    Christophylakis, C.
    Chainis, K.
    Kakolyris, S.
    Kalykaki, A.
    Mavroudis, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [39] Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group
    Inoue, Kenichi
    Nakagami, Kazuhiko
    Mizutani, Mitsuhiro
    Hozumi, Yasuo
    Fujiwara, Yasuhiro
    Masuda, Norikazu
    Tsukamoto, Fumine
    Saito, Mitsue
    Miura, Shigeto
    Eguchi, Kenji
    Shinkai, Tetsu
    Ando, Masashi
    Watanabe, Toru
    Masuda, Noriyuki
    Ohashi, Yasuo
    Sano, Muneaki
    Noguchi, Shinzaburo
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (01) : 127 - 136
  • [40] Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group
    Kenichi Inoue
    Kazuhiko Nakagami
    Mitsuhiro Mizutani
    Yasuo Hozumi
    Yasuhiro Fujiwara
    Norikazu Masuda
    Fumine Tsukamoto
    Mitsue Saito
    Shigeto Miura
    Kenji Eguchi
    Tetsu Shinkai
    Masashi Ando
    Toru Watanabe
    Noriyuki Masuda
    Yasuo Ohashi
    Muneaki Sano
    Shinzaburo Noguchi
    Breast Cancer Research and Treatment, 2010, 119 : 127 - 136
12345